ALNY Alnylam Pharmaceuticals Inc
Alnylam Pharmaceuticals Inc (ALNY) Insider Activity
What the officers, directors and large holders did with their own shares. Only open-market purchases and sales count toward the totals — grants, option exercises and shares withheld for tax are compensation mechanics, not decisions, and they're listed separately below.
How much of that selling was preplanned? 32% planned / 68% discretionary
Largest single sale: $545.4K.
Where they traded
No open-market insider purchase on record.
Recent open-market activity
| Date | Insider | Role | Action | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|---|
| PYOTT DAVID E I 5 fills | Director | Sell 10b5-1 | 3,830 | $299.18 | $1.1M | 4,491 −46% of holding | |
| McLaughlin Melissa 5 fills | Chief Human Resources Officer | Sell 10b5-1 | 2,286 | $330.42 | $755.3K | 11,673 −16.4% of holding | |
| McLaughlin Melissa 9 fills | Chief Human Resources Officer | Sell | 1,624 | $319.59 | $519.0K | 13,088 −11% of holding | |
| Garg Pushkal 4 fills | EVP Chief R&D | Sell 10b5-1 | 2,404 | $323.96 | $778.8K | 20,443 −10.5% of holding | |
| Fitzgerald Kevin Joseph 4 fills | CSO & EVP, Head of Research | Sell 10b5-1 | 658 | $323.98 | $213.2K | 21,103 −3% of holding | |
| Greenstreet Yvonne 8 fills | Chief Executive Officer | Sell | 2,933 | $323.08 | $947.6K | 98,493 −2.9% of holding | |
| Poulton Jeffrey V. 8 fills | EVP, Chief Financial Officer | Sell | 2,468 | $323.08 | $797.4K | 64,159 −3.7% of holding | |
| Garg Pushkal 8 fills | EVP Chief R&D | Sell | 2,309 | $323.08 | $746.0K | 23,300 −9% of holding | |
| Tanguler Tolga 8 fills | EVP, Chief Commercial Officer | Sell | 2,309 | $323.08 | $746.0K | 36,500 −5.9% of holding | |
| Fitzgerald Kevin Joseph 8 fills | CSO & EVP, Head of Research | Sell | 633 | $323.08 | $204.5K | 21,831 −2.8% of holding | |
| Garg Pushkal 4 fills | EVP Chief R&D | Sell 10b5-1 | 1,775 | $319.74 | $567.5K | 24,826 −6.7% of holding | |
| Fitzgerald Kevin Joseph 4 fills | CSO & EVP, Head of Research | Sell 10b5-1 | 1,652 | $319.73 | $528.2K | 23,223 −6.6% of holding |
Form 4s are due within two business days of a transaction, so this is close to real time — unlike the quarterly 13F data on the Institutional tab. A single large sale often reflects a prearranged 10b5-1 plan rather than a fresh view, so read a pattern of sales rather than any one of them.